Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06893016
PHASE3

Evaluation of RAY1225 in Adult Participants Who Have Obesity or Are Overweight

Sponsor: Guangdong Raynovent Biotech Co., Ltd

View on ClinicalTrials.gov

Summary

The primary objective of this study is to demonstrate that RAY1225 is superior to placebo for percent change in body weight.

Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study Evaluating the Safety, Tolerability, and Efficacy of RAY1225 in Participants Who Have Obesity or Are Overweight

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

640

Start Date

2025-06-15

Completion Date

2026-09-15

Last Updated

2025-07-17

Healthy Volunteers

No

Conditions

Interventions

DRUG

RAY1225

RAY1225 will be administered SC

DRUG

Placebo

Placebo will be administered SC.

Locations (1)

Peking University People's Hospital

Beijing, China